2022
The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis
Walker T, Miotto P, Köser C, Fowler P, Knaggs J, Iqbal Z, Hunt M, Chindelevitch L, Farhat M, Cirillo D, Comas I, Posey J, Omar S, Peto T, Suresh A, Uplekar S, Laurent S, Colman R, Nathanson C, Zignol M, Walker A, Crook D, Ismail N, Rodwell T, Consortium T, Walker A, Steyn A, Lalvani A, Baulard A, Christoffels A, Mendoza-Ticona A, Trovato A, Skrahina A, Lachapelle A, Brankin A, Piatek A, Cruz A, Koch A, Cabibbe A, Spitaleri A, Brandao A, Chaiprasert A, Suresh A, Barbova A, Van Rie A, Ghodousi A, Bainomugisa A, Mandal A, Roohi A, Javid B, Zhu B, Letcher B, Rodrigues C, Nimmo C, NATHANSON C, Duncan C, Coulter C, Utpatel C, Liu C, Grazian C, Kong C, Köser C, Wilson D, Cirillo D, Matias D, Jorgensen D, Zimenkov D, Chetty D, Moore D, Clifton D, Crook D, van Soolingen D, Liu D, Kohlerschmidt D, Barreira D, Ngcamu D, Lazaro E, Kelly E, Borroni E, Roycroft E, Andre E, Böttger E, Robinson E, Menardo F, Mendes F, Jamieson F, Coll F, Gao G, Kasule G, Rossolini G, Rodger G, Smith E, Meintjes G, Thwaites G, Hoffmann H, Albert H, Cox H, Laurenson I, Comas I, Arandjelovic I, Barilar I, Robledo J, Millard J, Johnston J, Posey J, Andrews J, Knaggs J, Gardy J, Guthrie J, Taylor J, Werngren J, Metcalfe J, Coronel J, Shea J, Carter J, Pinhata J, Kus J, Todt K, Holt K, Nilgiriwala K, Ghisi K, Malone K, Faksri K, Musser K, Joseph L, Rigouts L, Chindelevitch L, Jarrett L, Grandjean L, Ferrazoli L, Rodrigues M, Farhat M, Schito M, Fitzgibbon M, Loembé M, Wijkander M, Ballif M, Rabodoarivelo M, Mihalic M, WILCOX M, Hunt M, ZIGNOL M, Merker M, Egger M, O'Donnell M, Caws M, Wu M, Whitfield M, Inouye M, Mansjö M, Thi M, Joloba M, Kamal S, Okozi N, ISMAIL N, Mistry N, Hoang N, Rakotosamimanana N, Paton N, Rancoita P, Miotto P, Lapierre P, Hall P, Tang P, Claxton P, Wintringer P, Keller P, Thai P, Fowler P, Supply P, Srilohasin P, Suriyaphol P, Rathod P, Kambli P, Groenheit R, Colman R, Ong R, Warren R, Wilkinson R, Diel R, Oliveira R, Khot R, Jou R, Tahseen S, Laurent S, Gharbia S, Kouchaki S, Shah S, Plesnik S, Earle S, Dunstan S, Hoosdally S, Mitarai S, Gagneux S, Omar S, Yao S, Lapierre S, Battaglia S, Niemann S, Pandey S, Uplekar S, Halse T, Cohen T, Cortes T, Prammananan T, Kohl T, Thuong N, Teo T, Peto T, Rodwell T, William T, Walker T, Rogers T, Surve U, Mathys V, Furió V, Cook V, Vijay S, Escuyer V, Dreyer V, Sintchenko V, Saphonn V, Solano W, Lin W, van Gemert W, He W, Yang Y, Zhao Y, Qin Y, Xiao Y, Hasan Z, Iqbal Z, Puyen Z. The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis. The Lancet Microbe 2022, 3: e265-e273. PMID: 35373160, PMCID: PMC7612554, DOI: 10.1016/s2666-5247(21)00301-3.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsDrug ResistanceEthambutolMicrobial Sensitivity TestsMutationMycobacterium tuberculosisWorld Health OrganizationConceptsConsistent with susceptibilityAssociated with resistancePhenotypic resistanceDrug susceptibility testingSusceptibility testingPositive predictive valueAssociated with phenotypic resistanceWhole-genome sequencingPrevalence of phenotypic resistanceMolecular diagnosticsDrug susceptibility testing dataUniversal drug susceptibility testingMutations associated with drug resistanceOdds ratioSusceptibility testing dataDrug resistance predictionImplementation of molecular diagnosticsBinary phenotypesPredictive valueGene approachMTBC isolatesUnique mutationsFisher's exact testAnti-tuberculosis drugsGenotype analysis
2021
Global estimates of paediatric tuberculosis incidence in 2013–19: a mathematical modelling analysis
Yerramsetti S, Cohen T, Atun R, Menzies NA. Global estimates of paediatric tuberculosis incidence in 2013–19: a mathematical modelling analysis. The Lancet Global Health 2021, 10: e207-e215. PMID: 34895517, PMCID: PMC8800006, DOI: 10.1016/s2214-109x(21)00462-9.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge FactorsBayes TheoremChildChild, PreschoolFemaleGlobal HealthHumansIncidenceInfantMaleModels, TheoreticalRisk FactorsTuberculosisWorld Health OrganizationConceptsPediatric tuberculosisTuberculosis incidenceStudy periodIncident tuberculosis casesTuberculosis incidence rateReporting systemHigh-burden settingsGlobal tuberculosis burdenTuberculosis natural historyPediatric incidenceInfectious exposurePrompt diagnosisSubstantial morbidityTuberculosis burdenTuberculosis casesIncidence rateRisk factorsCase detectionGlobal incidenceProbability of infectionInfected individualsAge groupsNatural historyTuberculosisIncidence
2016
Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models
Houben RMGJ, Menzies NA, Sumner T, Huynh GH, Arinaminpathy N, Goldhaber-Fiebert JD, Lin HH, Wu CY, Mandal S, Pandey S, Suen SC, Bendavid E, Azman AS, Dowdy DW, Bacaër N, Rhines AS, Feldman MW, Handel A, Whalen CC, Chang ST, Wagner BG, Eckhoff PA, Trauer JM, Denholm JT, McBryde ES, Cohen T, Salomon JA, Pretorius C, Lalli M, Eaton JW, Boccia D, Hosseini M, Gomez GB, Sahu S, Daniels C, Ditiu L, Chin DP, Wang L, Chadha VK, Rade K, Dewan P, Hippner P, Charalambous S, Grant AD, Churchyard G, Pillay Y, Mametja LD, Kimerling ME, Vassall A, White RG. Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. The Lancet Global Health 2016, 4: e806-e815. PMID: 27720688, PMCID: PMC6375908, DOI: 10.1016/s2214-109x(16)30199-1.Peer-Reviewed Original ResearchConceptsEnd TB Strategy targetsPreventive therapyTuberculosis incidenceContinuous isoniazid preventive therapyGlobal tuberculosis targetsIsoniazid preventive therapySymptoms of tuberculosisActive case findingNational Tuberculosis ProgrammeEnd TB StrategyHigh-burden countriesAntiretroviral therapyLatent tuberculosisStrategy targetsTuberculosis burdenTuberculosis careTuberculosis ProgrammeTB StrategyTuberculosis transmissionHealth centersAdditional interventionsTuberculosis interventionsCase findingTuberculosis epidemiologyEpidemiological impact
2015
Counting children with tuberculosis: why numbers matter
Seddon JA, Jenkins HE, Liu L, Cohen T, Black RE, Vos T, Becerra MC, Graham SM, Sismanidis C, Dodd PJ. Counting children with tuberculosis: why numbers matter. The International Journal Of Tuberculosis And Lung Disease 2015, 19: 9-16. PMID: 26564535, PMCID: PMC4708268, DOI: 10.5588/ijtld.15.0471.Peer-Reviewed Original Research
2014
On the spread and control of MDR-TB epidemics: An examination of trends in anti-tuberculosis drug resistance surveillance data
Cohen T, Jenkins HE, Lu C, McLaughlin M, Floyd K, Zignol M. On the spread and control of MDR-TB epidemics: An examination of trends in anti-tuberculosis drug resistance surveillance data. Drug Resistance Updates 2014, 17: 105-123. PMID: 25458783, PMCID: PMC4358299, DOI: 10.1016/j.drup.2014.10.001.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsHumansPopulation SurveillanceTuberculosis, Multidrug-ResistantWorld Health OrganizationConceptsMDR-TBTB casesResistant tuberculosisAbsolute burdenSurveillance dataMDR-TB epidemicDrug-resistant TBMultidrug-resistant tuberculosisDrug-resistant tuberculosisNotified TB casesResistance surveillance dataSufficient surveillance dataWorld Health OrganizationBurden settingsTuberculosis controlUnadjusted analysesSignificant linear trendSurveillance indicatorsRobust surveillance systemHealth OrganizationTuberculosisBurdenSurveillance systemSettingLinear trend
2011
Quantifying the Burden and Trends of Isoniazid Resistant Tuberculosis, 1994–2009
Jenkins HE, Zignol M, Cohen T. Quantifying the Burden and Trends of Isoniazid Resistant Tuberculosis, 1994–2009. PLOS ONE 2011, 6: e22927. PMID: 21829557, PMCID: PMC3146514, DOI: 10.1371/journal.pone.0022927.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapyIncident TB casesTB casesHIV prevalence countriesHigh HIV prevalence countriesPrevalence countriesHigh HIV prevalence areasRetreatment TB casesHIV prevalence areasIsoniazid-resistant tuberculosisControl of tuberculosisEffect of INHObserved time trendsWorld Health OrganizationPreventive therapyResistant tuberculosisIncident casesTreatment successPrevalence areasIsoniazid resistanceMultidrug resistanceHealth OrganizationTuberculosisINHNational data